Human parvovirus B19 in pediatric and adult recipients of allogeneic hematopoietic stem cell transplantation

Öhrmalm, Lars; Gustafson, Ingvar; Lindblom, Anna; Norbeck, Oscar; Johansson, J-E; Brüne, Martin; Ljungman, Per; Broliden, Kristina

doi:10.1038/bmt.2013.110

Cited by 8 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the opposite, when the immune system has not the capability to control, neutralize and clear viral infection, infection can become persistent, with active viral replication and the involvement to different degrees of erythroid compartment. These last situations can be typical of congenital or acquired immunodeficiency, such as HIV-infection (46), in cases of malignancies (20), in the course of chemotherapy (56), or in the course of immunosuppressive treatments, such as in bone marrow (75) or solid organ transplant recipients (31). Depression of erythropoiesis can be manifest, with anaemia of different grade, but also compensated and unapparent.…”

Section: How Many Pathologies?mentioning

confidence: 99%

Parvovirus B19: recent insights and implications for pathogenesis, diagnosis and therapy

Gallinella

2017

Microbiol Med

View full text Add to dashboard Cite

Parvovirus B19 is a human pathogenic virus, a ssDNA member of the family Parvoviridae, characterized by a selective tropism for erythroid progenitor cells (EPCs) in the bone marrow and an ample pathogenetic potential. The selective tropism for EPCs can be explained both in terms of receptor-mediated tropism and of an intracellular permissive environment conditioned by the cell differentiation and proliferation stage. Infection of EPCs is productive, induces apoptosis and leads to a temporary arrest of erythropoiesis, which can usually be manifest in cases of underlying erythropoietic disorders or immune system deficiencies. Endothelial cells constitute an additional diffuse target, whose infection is mediated by ADE phenomenon, but is normally nonproductive and mainly leading to inflammatory processes. The relevance of parvovirus as a cardiotropic virus is recently emerging, while its capability of intrauterine transmission and consequences on the fetus is known and should not be overlooked. To the purpose of diagnosis, a combination of molecular and immunological methods offers the best discrimination of active infectious processes, and an application of these methods especially in cases of atypical presentations should be encouraged. Ongoing research is directed towards the development of a vaccine and the discovery of antiviral drugs that may be useful in the prevention and treatment of parvovirus B19 infections.

show abstract

Section: How Many Pathologies?mentioning

confidence: 99%

Parvovirus B19: recent insights and implications for pathogenesis, diagnosis and therapy

Gallinella

2017

Microbiol Med

View full text Add to dashboard Cite

show abstract

“…In most cases, the patients presented with prolonged cytopenia, one showed a focal skin lesion, and one had a skin rash. All cases with more detailed clinical information are summarized in Table 2 22–30 …”

Section: Resultsmentioning

confidence: 99%

“…All cases with more detailed clinical information are summarized in Table 2. [22][23][24][25][26][27][28][29][30] Rahiala et al screened a pediatric cohort of 53 patients receiving allogeneic HCT for the appearance of B19V DNA prior to and following transplantation. At least one positive B19V PCR was found in 30% of the patients, and 8.3 % of all serum samples taken after transplantation were positive for B19V DNA.…”

Section: Katoh Et Al Report Five Patients With B19v Infection After A...mentioning

confidence: 99%

Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation – Single‐center experience and review

Holterhus

Hennies

Hillmann

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

Background Parvovirus B19 (B19V) infection following pediatric hematopoietic cell transplantation (HCT) is a rare complication and available data is scarce. Therefore, we present the experience with B19V Infection in allogeneic pediatric HCT recipients at our transplant center together with a systematic review of the literature. Methods Pediatric HCT patients with Parvovirus B19 infection treated at the University Children's Hospital Münster between 1999 and 2021 were retrospectively identified and clinical data were analyzed. Additionally, a systematic MEDLINE search to identify relevant articles was performed. Results We identified three out of 445 patients (0.6%) with B19V infection post‐transplantation. B19V infection occurred in combination with other complications like Graft‐versus‐Host disease, additional infections, or autoimmune‐mediated hemolysis potentially triggered by B19V. In one patient these complications lead to a fatal outcome. The review of the literature showed considerable morbidity of B19V infection with the potential for life‐threatening complications. Most patients were treated by red blood cell transfusion and intravenous immunoglobulins (IVIG) with a high succession rate. Conclusion Symptomatic B19V infection following HCT remains a rare but potentially challenging complication. A causal antiviral therapy does not exist as well as general recommendations on dosage and duration of IVIG therapy. Despite this, most patients are treated successfully with these measures. Additionally, transmission via blood or stem cell products is also rare and no general recommendations on B19V screenings exist.

show abstract

“…The frequency of B19V‐attributable anemia in kidney transplant recipients represents the rate of B19V‐attributable anemia or cytopenia and can be extrapolated to other solid organ transplant (SOT) recipients. It was unclear what this rate may be because few studies were available; therefore, risk was estimated for three values: 10%, 50%, and the intermediate value of 30%. The burden of B19V‐associated complications is much lower for hematopoietic stem cell transplant than SOT recipients . The specific rate is unclear; therefore, risk was estimated for three values: 1%, 5%, and 10%. The number of red blood cells (RBCs) transfused to patients with hereditary hemolytic anemias (HHAs) per year is approximately equal to national hospital separations for these conditions with equivalent RBC use patterns to those reported in a 2011 South Australian study …”

Section: Methodsmentioning

confidence: 99%

Modeling the parvovirus B19 blood safety risk in Australia

et al. 2018

View full text Add to dashboard Cite

BACKGROUND: Three probable cases of transfusiontransmitted (TT) parvovirus B19 (B19V) occurred in Australia between 2014 and 2017. This study aimed to determine the B19V DNA prevalence among blood donors, to model the risk to recipients of fresh components, and to assess risk management options. ABBREVIATIONS: B19V = parvovirus B19; HHA = hereditary hemolytic anemia; Ig = immunoglobin; MPC = Melbourne Processing Centre; NAT = nucleic acid amplification; PAF = population-attributable fraction; PI = pathogen inactivation; RBC = red blood cell; SCD = sickle cell disease; SOT = solid organ transplant; TAC = transient aplastic crisis; TT = transfusion transmitted.

show abstract

Human parvovirus B19 in pediatric and adult recipients of allogeneic hematopoietic stem cell transplantation

Cited by 8 publications

References 10 publications

Parvovirus B19: recent insights and implications for pathogenesis, diagnosis and therapy

Parvovirus B19: recent insights and implications for pathogenesis, diagnosis and therapy

Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation – Single‐center experience and review

Modeling the parvovirus B19 blood safety risk in Australia

Contact Info

Product

Resources

About